Literature DB >> 31291494

The cost and the value of treatment of medication overuse headache in Italy: a longitudinal study based on patient-derived data.

A Raggi1, M Leonardi1, E Sansone1, M Curone2, L Grazzi3, D D'Amico3.   

Abstract

BACKGROUND AND
PURPOSE: The cost of medication overuse headache (MOH) is underestimated. Our aim was to address the cost-effectiveness of a structured treatment protocol and to present annual cost estimates.
METHODS: Patients were enrolled on the occasion of a structured treatment protocol, were administered a research protocol addressing direct and indirect costs and were followed up for 3 months.
RESULTS: Of 176 enrolled patients, 138 completed the study. The 3-month cost per patient fell from €2989 to €1160: the difference was €696 per month for patients treated in the ward and €466 for those treated in day-hospital; thus it takes 2-3 months to compensate for the protocol's cost. The per-person annual costs of MOH were €10 533 (95% confidence interval €8700-12 406): direct healthcare costs accounted for 44.8% and indirect costs for 51.5% of the total MOH cost. The annual MOH cost for Italy is estimated at €13.5 billion (95% confidence interval €11.1-15.9 billion).
CONCLUSION: The cost of MOH around the period of a structured treatment protocol is much higher compared to previous estimates. Our protocol is cost-effective for reducing the economic burden of MOH. © European Academy of Neurology 2019.

Entities:  

Keywords:  burden; chronic migraine; chronic tension-type headache; cost; detoxification; medication overuse headache; non-pharmacological treatment; withdrawal

Mesh：

Substances：

Year:  2019        PMID： 31291494     DOI： 10.1111/ene.14034

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN： 1351-5101            Impact factor:   6.089


  10 in total

1.  Comparison of 3 Treatment Strategies for Medication Overuse Headache: A Randomized Clinical Trial.

Authors:  Louise Ninett Carlsen; Signe Bruun Munksgaard; Mia Nielsen; Ida Maria Storm Engelstoft; Maria Lurenda Westergaard; Lars Bendtsen; Rigmor Højland Jensen
Journal:  JAMA Neurol       Date:  2020-09-01       Impact factor: 18.302

2.  Addressing the cost of chronic and episodic migraine and its main drivers: a short-term longitudinal analysis from a third-level Italian center.

Authors:  Alberto Raggi; Licia Grazzi; Erika Guastafierro; Alessia Marcassoli; Marco Passavanti; Danilo Antonio Montisano; Domenico D'Amico
Journal:  Neurol Sci       Date:  2022-05-27       Impact factor: 3.830

3.  Pain rates in general population for the period 1991-2015 and 10-years prediction: results from a multi-continent age-period-cohort analysis.

Authors:  Davide Guido; Matilde Leonardi; Blanca Mellor-Marsá; Maria V Moneta; Albert Sanchez-Niubo; Stefanos Tyrovolas; Iago Giné-Vázquez; Josep M Haro; Somnath Chatterji; Martin Bobak; Jose L Ayuso-Mateos; Holger Arndt; Ilona Koupil; Jerome Bickenbach; Seppo Koskinen; Beata Tobiasz-Adamczyk; Demosthenes Panagiotakos; Alberto Raggi
Journal:  J Headache Pain       Date:  2020-05-13       Impact factor: 7.277

4.  Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache.

Authors:  Jill C Rau; Edita Navratilova; Janice Oyarzo; Kirk W Johnson; Sheena K Aurora; Todd J Schwedt; David W Dodick; Frank Porreca
Journal:  Cephalalgia       Date:  2020-06-24       Impact factor: 6.292

5.  Analysis of treatment cost and persistence among migraineurs: A two-year retrospective cohort study in Pakistan.

Authors:  Kamran Khan; Mudassar Iqbal Arain; Muhammad Arif Asghar; Ahad Abdul Rehman; Muhammad Ali Ghoto; Abdullah Dayo; Muhammad Suleman Imtiaz; Mohsin Hamied Rana; Muhammad Asif Asghar
Journal:  PLoS One       Date:  2021-03-26       Impact factor: 3.240

6.  Migraine Outcome Should Not Be Used to Determine Diagnosis, Severity, and Therapy: Moving Towards a Multiparametric Definition of Chronicity.

Authors:  Alberto Raggi; Matilde Leonardi; Simona Sacco; Paolo Martelletti
Journal:  Pain Ther       Date:  2022-03-29

7.  Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache.

Authors:  Umberto Pensato; Carlo Baraldi; Valentina Favoni; Davide Mascarella; Eleonora Matteo; Giorgia Andrini; Maria Michela Cainazzo; Pietro Cortelli; Giulia Pierangeli; Simona Guerzoni; Sabina Cevoli
Journal:  Cephalalgia       Date:  2022-02-09       Impact factor: 6.075

Review 8.  Applying a biopsychosocial model to migraine: rationale and clinical implications.

Authors:  Chiara Rosignoli; Raffaele Ornello; Agnese Onofri; Valeria Caponnetto; Licia Grazzi; Alberto Raggi; Matilde Leonardi; Simona Sacco
Journal:  J Headache Pain       Date:  2022-08-11       Impact factor: 8.588

9.  The Ruminative Thought Style with Associated Anxiety Influences the Occurrence of Medication-Overuse Headache.

Authors:  Marina Ljubisavljevic; Aleksandra Ignjatovic; Srdjan Ljubisavljevic
Journal:  J Clin Neurol       Date:  2021-07       Impact factor: 3.077

Review 10.  Comorbidities of primary headache disorders: a literature review with meta-analysis.

Authors:  Valeria Caponnetto; Manuela Deodato; Paolo Martelletti; Alberto Raggi; Micaela Robotti; Maria Koutsokera; Valeria Pozzilli; Cristina Galati; Giovanna Nocera; Eleonora De Matteis; Gioacchino De Vanna; Emanuela Fellini; Gleni Halili; Daniele Martinelli; Gabriele Nalli; Serena Serratore; Irene Tramacere
Journal:  J Headache Pain       Date:  2021-07-14       Impact factor: 7.277
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.